Microbiome-Empowered Therapeutics

Harnessing the therapeutic power of the human microbiome

Biomica is a clinical-stage biopharmaceutical company dedicated to developing innovative microbiome-based therapeutics for the treatment of cancer, immune-mediated, and infectious diseases. Synergizing proprietary big data and computational capabilities, Biomica develops best-in-class therapeutics to address high-value, unmet medical needs.

Minimal Number of Strains. Maximal Efficacy.

Our unique approach is focused on understanding the functional elements of the microbiome. This enables us to select a minimal number of desired microbial candidates, thereby maximizing beneficial effects while minimizing potential adverse effects through carefully curated consortia.

Proven Technology. Unmatched Computational Power.

Our drug candidates have been identified and designed using PRISM, a proprietary cutting-edge computational platform that integrates advanced AI capabilities, ‘Big Data’, and a comprehensive proprietary database. Through metagenomics sequencing, Biomica gains deeper insights into the microbiome, employing high-resolution taxonomy and functional profiling of the human microbiome. These insights enable us to develop novel solutions for complex host-microbiome interrelations and make clinically relevant predictions.

Highlighted News About Biomica

Jan 27, 2025

2025 J.P. Morgan Annual Healthcare week

Dr. Elran Haber, CEO of Biomica will be attending Biotech Showcase 2025 as part of the J.P. Morgan Annual Healthcare week in San Francisco. If you’d like to meet with Dr. Haber, please get in touch through the partnering platform or DM us.

Jan 27, 2025

Biomica’s Investor Meeting & Workshop

Biomica was delighted to host an inspiring investor meeting and workshop in Hong Kong, bringing together leading academics, local investors, researchers, and partners. Dr. Elran Haber, Biomica’s CEO, presented the company’s cutting-edge advancements in microbiome-based therapeutics, while Prof. Gal Markel shared his insights into the recent positive Ph1 results and the transformative potential of these […]

Jan 27, 2025

Microbiome Connect USA

Biomica’s CEO, Dr. Elran Haber, will be a featured panelist at the Microbiome Connect USA event on Wednesday, November 20, at 9:30 AM (local time). Join him for the session: “Taking the Bird’s Eye View: Market Insights & Dynamics of Microbiome Drug Development”.